Loading…
Arterial Destiffening With Atorvastatin in Overweight and Obese Middle-Aged and Older Adults
We hypothesized that atorvastatin (ATOR) treatment would reduce arterial stiffness in overweight and obese middle-aged and older adults. Twenty-six (11 men and 15 women) overweight or obese (body mass index31.6±0.7 kg/m) middle-aged and older adults (age54±2 years) were randomly assigned to receive...
Saved in:
| Published in: | Hypertension (Dallas, Tex. 1979) Tex. 1979), 2009-10, Vol.54 (4), p.763-768 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4338-eef68b35a80948fdeabc4aab0d04a206c1645eefd6c42b8ae78fe51e407d0ad83 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4338-eef68b35a80948fdeabc4aab0d04a206c1645eefd6c42b8ae78fe51e407d0ad83 |
| container_end_page | 768 |
| container_issue | 4 |
| container_start_page | 763 |
| container_title | Hypertension (Dallas, Tex. 1979) |
| container_volume | 54 |
| creator | Orr, Jeb S Dengo, A Laura Rivero, Jose M Davy, Kevin P |
| description | We hypothesized that atorvastatin (ATOR) treatment would reduce arterial stiffness in overweight and obese middle-aged and older adults. Twenty-six (11 men and 15 women) overweight or obese (body mass index31.6±0.7 kg/m) middle-aged and older adults (age54±2 years) were randomly assigned to receive either ATOR (80 mg/d) or placebo for 12 weeks. Arterial stiffness (β-stiffness and pulse wave velocity) was measured before and after the intervention. At baseline, the ATOR (n=16) and placebo (n=10) groups did not differ with respect to age, body mass index, blood pressure, serum lipid and lipoprotein concentrations, high-sensitivity C-reactive protein, indices of arterial stiffness, or compliance (all P>0.05). After the 12-week treatment period, the ATOR group experienced a 47% reduction in low-density lipoprotein cholesterol (149±6 to 80±8 mg/dL) and a 42% reduction in high-sensitivity C-reactive protein (3.6±0.8 to 2.1±0.5 mg/L; both P0.05). However, the reductions in arterial stiffness were correlated with the reduction in low-density lipoprotein cholesterol but not high-sensitivity C-reactive protein or any other cardiometabolic variables (all P |
| doi_str_mv | 10.1161/HYPERTENSIONAHA.109.138248 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67658192</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67658192</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4338-eef68b35a80948fdeabc4aab0d04a206c1645eefd6c42b8ae78fe51e407d0ad83</originalsourceid><addsrcrecordid>eNpdkW2L1DAQgIMo3nr6F6QI-q1r3pqmfit3q3tw3oqeqCCEaTPdjWbbM2lv8d-bpYuCISFkeCbJPEPIC0aXjCn2ev3tw-rj7erm09Xmpl7XS0arJROaS_2ALFjBZS4LJR6SBWWVzCvGvp6RJzH-oJRJKcvH5IxVSpdCigX5XocRgwOfXWIcXddh7_pt9sWNu6weh3APcYTR9Vmam3sMB3Tb3ZhBb7NNgxGz985aj3m9RTtHvcWQ1XbyY3xKHnXgIz477efk89vV7cU6v968u7qor_NWCqFzxE7pRhSgaSV1ZxGaVgI01FIJnKqWKVkkyKpW8kYDlrrDgqGkpaVgtTgnr-Z778Lwa0p1mL2LLXoPPQ5TNKpUhWYVT-CbGWzDEGPAztwFt4fw2zBqjm7Nf25TvDKz25T8_PTK1OzR_ks9yUzAyxMAsQXfBehbF_9yPHWDc3r8hZy5w-CT_PjTTwcMZofgx52haUiudM4prdjxlKfFtPgDOMqU7g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67658192</pqid></control><display><type>article</type><title>Arterial Destiffening With Atorvastatin in Overweight and Obese Middle-Aged and Older Adults</title><source>EZB Electronic Journals Library</source><creator>Orr, Jeb S ; Dengo, A Laura ; Rivero, Jose M ; Davy, Kevin P</creator><creatorcontrib>Orr, Jeb S ; Dengo, A Laura ; Rivero, Jose M ; Davy, Kevin P</creatorcontrib><description>We hypothesized that atorvastatin (ATOR) treatment would reduce arterial stiffness in overweight and obese middle-aged and older adults. Twenty-six (11 men and 15 women) overweight or obese (body mass index31.6±0.7 kg/m) middle-aged and older adults (age54±2 years) were randomly assigned to receive either ATOR (80 mg/d) or placebo for 12 weeks. Arterial stiffness (β-stiffness and pulse wave velocity) was measured before and after the intervention. At baseline, the ATOR (n=16) and placebo (n=10) groups did not differ with respect to age, body mass index, blood pressure, serum lipid and lipoprotein concentrations, high-sensitivity C-reactive protein, indices of arterial stiffness, or compliance (all P>0.05). After the 12-week treatment period, the ATOR group experienced a 47% reduction in low-density lipoprotein cholesterol (149±6 to 80±8 mg/dL) and a 42% reduction in high-sensitivity C-reactive protein (3.6±0.8 to 2.1±0.5 mg/L; both P<0.05). In addition, β-stiffness (9.4±0.6 to 7.6±0.5 U) and aortic pulse wave velocity (1096±36 to 932±32 cm/s), but not brachial pulse wave velocity, decreased (both P<0.05) with ATOR. In contrast, there were no significant changes in β-stiffness (9.1±0.8 to 9.1±0.7 U) or aortic pulse wave velocity (1238±89 to 1191±90 cm/s; both P>0.05) in the placebo group. There were no relations between the reductions in arterial stiffness indices and any of the baseline cardiometabolic risk factors (all P>0.05). However, the reductions in arterial stiffness were correlated with the reduction in low-density lipoprotein cholesterol but not high-sensitivity C-reactive protein or any other cardiometabolic variables (all P<0.05). Taken together, these findings suggest that ATOR reduces arterial stiffness in overweight and obese middle-aged and older adults, and these favorable changes occur irrespective of baseline cardiometabolic risk factors.</description><identifier>ISSN: 0194-911X</identifier><identifier>EISSN: 1524-4563</identifier><identifier>DOI: 10.1161/HYPERTENSIONAHA.109.138248</identifier><identifier>PMID: 19687343</identifier><identifier>CODEN: HPRTDN</identifier><language>eng</language><publisher>Hagerstown, MD: American Heart Association, Inc</publisher><subject>Adult ; Aged ; Aging - physiology ; Arterial hypertension. Arterial hypotension ; Atorvastatin Calcium ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood Flow Velocity - drug effects ; Blood Flow Velocity - physiology ; C-Reactive Protein - metabolism ; Cardiology. Vascular system ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - physiopathology ; Carotid Arteries - drug effects ; Carotid Arteries - physiopathology ; Cholesterol, LDL - blood ; Double-Blind Method ; Elasticity - drug effects ; Female ; Femoral Artery - drug effects ; Femoral Artery - physiopathology ; Heptanoic Acids - pharmacology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; Obesity ; Obesity - physiopathology ; Overweight - physiopathology ; Pyrroles - pharmacology ; Regional Blood Flow - drug effects ; Regional Blood Flow - physiology ; Risk Factors</subject><ispartof>Hypertension (Dallas, Tex. 1979), 2009-10, Vol.54 (4), p.763-768</ispartof><rights>2009 American Heart Association, Inc.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4338-eef68b35a80948fdeabc4aab0d04a206c1645eefd6c42b8ae78fe51e407d0ad83</citedby><cites>FETCH-LOGICAL-c4338-eef68b35a80948fdeabc4aab0d04a206c1645eefd6c42b8ae78fe51e407d0ad83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21942202$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19687343$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orr, Jeb S</creatorcontrib><creatorcontrib>Dengo, A Laura</creatorcontrib><creatorcontrib>Rivero, Jose M</creatorcontrib><creatorcontrib>Davy, Kevin P</creatorcontrib><title>Arterial Destiffening With Atorvastatin in Overweight and Obese Middle-Aged and Older Adults</title><title>Hypertension (Dallas, Tex. 1979)</title><addtitle>Hypertension</addtitle><description>We hypothesized that atorvastatin (ATOR) treatment would reduce arterial stiffness in overweight and obese middle-aged and older adults. Twenty-six (11 men and 15 women) overweight or obese (body mass index31.6±0.7 kg/m) middle-aged and older adults (age54±2 years) were randomly assigned to receive either ATOR (80 mg/d) or placebo for 12 weeks. Arterial stiffness (β-stiffness and pulse wave velocity) was measured before and after the intervention. At baseline, the ATOR (n=16) and placebo (n=10) groups did not differ with respect to age, body mass index, blood pressure, serum lipid and lipoprotein concentrations, high-sensitivity C-reactive protein, indices of arterial stiffness, or compliance (all P>0.05). After the 12-week treatment period, the ATOR group experienced a 47% reduction in low-density lipoprotein cholesterol (149±6 to 80±8 mg/dL) and a 42% reduction in high-sensitivity C-reactive protein (3.6±0.8 to 2.1±0.5 mg/L; both P<0.05). In addition, β-stiffness (9.4±0.6 to 7.6±0.5 U) and aortic pulse wave velocity (1096±36 to 932±32 cm/s), but not brachial pulse wave velocity, decreased (both P<0.05) with ATOR. In contrast, there were no significant changes in β-stiffness (9.1±0.8 to 9.1±0.7 U) or aortic pulse wave velocity (1238±89 to 1191±90 cm/s; both P>0.05) in the placebo group. There were no relations between the reductions in arterial stiffness indices and any of the baseline cardiometabolic risk factors (all P>0.05). However, the reductions in arterial stiffness were correlated with the reduction in low-density lipoprotein cholesterol but not high-sensitivity C-reactive protein or any other cardiometabolic variables (all P<0.05). Taken together, these findings suggest that ATOR reduces arterial stiffness in overweight and obese middle-aged and older adults, and these favorable changes occur irrespective of baseline cardiometabolic risk factors.</description><subject>Adult</subject><subject>Aged</subject><subject>Aging - physiology</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Atorvastatin Calcium</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood Flow Velocity - drug effects</subject><subject>Blood Flow Velocity - physiology</subject><subject>C-Reactive Protein - metabolism</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - physiopathology</subject><subject>Carotid Arteries - drug effects</subject><subject>Carotid Arteries - physiopathology</subject><subject>Cholesterol, LDL - blood</subject><subject>Double-Blind Method</subject><subject>Elasticity - drug effects</subject><subject>Female</subject><subject>Femoral Artery - drug effects</subject><subject>Femoral Artery - physiopathology</subject><subject>Heptanoic Acids - pharmacology</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Obesity - physiopathology</subject><subject>Overweight - physiopathology</subject><subject>Pyrroles - pharmacology</subject><subject>Regional Blood Flow - drug effects</subject><subject>Regional Blood Flow - physiology</subject><subject>Risk Factors</subject><issn>0194-911X</issn><issn>1524-4563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNpdkW2L1DAQgIMo3nr6F6QI-q1r3pqmfit3q3tw3oqeqCCEaTPdjWbbM2lv8d-bpYuCISFkeCbJPEPIC0aXjCn2ev3tw-rj7erm09Xmpl7XS0arJROaS_2ALFjBZS4LJR6SBWWVzCvGvp6RJzH-oJRJKcvH5IxVSpdCigX5XocRgwOfXWIcXddh7_pt9sWNu6weh3APcYTR9Vmam3sMB3Tb3ZhBb7NNgxGz985aj3m9RTtHvcWQ1XbyY3xKHnXgIz477efk89vV7cU6v968u7qor_NWCqFzxE7pRhSgaSV1ZxGaVgI01FIJnKqWKVkkyKpW8kYDlrrDgqGkpaVgtTgnr-Z778Lwa0p1mL2LLXoPPQ5TNKpUhWYVT-CbGWzDEGPAztwFt4fw2zBqjm7Nf25TvDKz25T8_PTK1OzR_ks9yUzAyxMAsQXfBehbF_9yPHWDc3r8hZy5w-CT_PjTTwcMZofgx52haUiudM4prdjxlKfFtPgDOMqU7g</recordid><startdate>200910</startdate><enddate>200910</enddate><creator>Orr, Jeb S</creator><creator>Dengo, A Laura</creator><creator>Rivero, Jose M</creator><creator>Davy, Kevin P</creator><general>American Heart Association, Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200910</creationdate><title>Arterial Destiffening With Atorvastatin in Overweight and Obese Middle-Aged and Older Adults</title><author>Orr, Jeb S ; Dengo, A Laura ; Rivero, Jose M ; Davy, Kevin P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4338-eef68b35a80948fdeabc4aab0d04a206c1645eefd6c42b8ae78fe51e407d0ad83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aging - physiology</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Atorvastatin Calcium</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood Flow Velocity - drug effects</topic><topic>Blood Flow Velocity - physiology</topic><topic>C-Reactive Protein - metabolism</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - physiopathology</topic><topic>Carotid Arteries - drug effects</topic><topic>Carotid Arteries - physiopathology</topic><topic>Cholesterol, LDL - blood</topic><topic>Double-Blind Method</topic><topic>Elasticity - drug effects</topic><topic>Female</topic><topic>Femoral Artery - drug effects</topic><topic>Femoral Artery - physiopathology</topic><topic>Heptanoic Acids - pharmacology</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Obesity - physiopathology</topic><topic>Overweight - physiopathology</topic><topic>Pyrroles - pharmacology</topic><topic>Regional Blood Flow - drug effects</topic><topic>Regional Blood Flow - physiology</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orr, Jeb S</creatorcontrib><creatorcontrib>Dengo, A Laura</creatorcontrib><creatorcontrib>Rivero, Jose M</creatorcontrib><creatorcontrib>Davy, Kevin P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orr, Jeb S</au><au>Dengo, A Laura</au><au>Rivero, Jose M</au><au>Davy, Kevin P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Arterial Destiffening With Atorvastatin in Overweight and Obese Middle-Aged and Older Adults</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><addtitle>Hypertension</addtitle><date>2009-10</date><risdate>2009</risdate><volume>54</volume><issue>4</issue><spage>763</spage><epage>768</epage><pages>763-768</pages><issn>0194-911X</issn><eissn>1524-4563</eissn><coden>HPRTDN</coden><abstract>We hypothesized that atorvastatin (ATOR) treatment would reduce arterial stiffness in overweight and obese middle-aged and older adults. Twenty-six (11 men and 15 women) overweight or obese (body mass index31.6±0.7 kg/m) middle-aged and older adults (age54±2 years) were randomly assigned to receive either ATOR (80 mg/d) or placebo for 12 weeks. Arterial stiffness (β-stiffness and pulse wave velocity) was measured before and after the intervention. At baseline, the ATOR (n=16) and placebo (n=10) groups did not differ with respect to age, body mass index, blood pressure, serum lipid and lipoprotein concentrations, high-sensitivity C-reactive protein, indices of arterial stiffness, or compliance (all P>0.05). After the 12-week treatment period, the ATOR group experienced a 47% reduction in low-density lipoprotein cholesterol (149±6 to 80±8 mg/dL) and a 42% reduction in high-sensitivity C-reactive protein (3.6±0.8 to 2.1±0.5 mg/L; both P<0.05). In addition, β-stiffness (9.4±0.6 to 7.6±0.5 U) and aortic pulse wave velocity (1096±36 to 932±32 cm/s), but not brachial pulse wave velocity, decreased (both P<0.05) with ATOR. In contrast, there were no significant changes in β-stiffness (9.1±0.8 to 9.1±0.7 U) or aortic pulse wave velocity (1238±89 to 1191±90 cm/s; both P>0.05) in the placebo group. There were no relations between the reductions in arterial stiffness indices and any of the baseline cardiometabolic risk factors (all P>0.05). However, the reductions in arterial stiffness were correlated with the reduction in low-density lipoprotein cholesterol but not high-sensitivity C-reactive protein or any other cardiometabolic variables (all P<0.05). Taken together, these findings suggest that ATOR reduces arterial stiffness in overweight and obese middle-aged and older adults, and these favorable changes occur irrespective of baseline cardiometabolic risk factors.</abstract><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><pmid>19687343</pmid><doi>10.1161/HYPERTENSIONAHA.109.138248</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0194-911X |
| ispartof | Hypertension (Dallas, Tex. 1979), 2009-10, Vol.54 (4), p.763-768 |
| issn | 0194-911X 1524-4563 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67658192 |
| source | EZB Electronic Journals Library |
| subjects | Adult Aged Aging - physiology Arterial hypertension. Arterial hypotension Atorvastatin Calcium Biological and medical sciences Blood and lymphatic vessels Blood Flow Velocity - drug effects Blood Flow Velocity - physiology C-Reactive Protein - metabolism Cardiology. Vascular system Cardiovascular Diseases - epidemiology Cardiovascular Diseases - physiopathology Carotid Arteries - drug effects Carotid Arteries - physiopathology Cholesterol, LDL - blood Double-Blind Method Elasticity - drug effects Female Femoral Artery - drug effects Femoral Artery - physiopathology Heptanoic Acids - pharmacology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Male Medical sciences Metabolic diseases Middle Aged Obesity Obesity - physiopathology Overweight - physiopathology Pyrroles - pharmacology Regional Blood Flow - drug effects Regional Blood Flow - physiology Risk Factors |
| title | Arterial Destiffening With Atorvastatin in Overweight and Obese Middle-Aged and Older Adults |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A06%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Arterial%20Destiffening%20With%20Atorvastatin%20in%20Overweight%20and%20Obese%20Middle-Aged%20and%20Older%20Adults&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=Orr,%20Jeb%20S&rft.date=2009-10&rft.volume=54&rft.issue=4&rft.spage=763&rft.epage=768&rft.pages=763-768&rft.issn=0194-911X&rft.eissn=1524-4563&rft.coden=HPRTDN&rft_id=info:doi/10.1161/HYPERTENSIONAHA.109.138248&rft_dat=%3Cproquest_cross%3E67658192%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4338-eef68b35a80948fdeabc4aab0d04a206c1645eefd6c42b8ae78fe51e407d0ad83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67658192&rft_id=info:pmid/19687343&rfr_iscdi=true |